上周，全球银行业迎来一年一度的"大戏"。业内最权威的媒体，英国《金融时报》旗下《银行家》杂志发布了 2025 年度全球银行 1000 强榜单，中资银行 继续占据重要位置。 其中，在排名前五十的银行中，工商银行、建设银行、农业银行、中国银行仍然稳居前四；招商银行排名超越交通银行，升至第8位；交通银行为第9位。 从一级资本规模来看，工商银行以5410.21亿美元的一级资本位列前茅，比排名第5的摩根大通高出近2500亿美元。建设银行和农业银行的一级资本均超过 4000亿美元，分别达到4554.01亿美元和4221.73亿美元。中国银行的一级资本也超过3000亿美元，为3785.32亿美元。 在此次排名中，除了前述银行，还有招商银行和交通银行这两家中资银行跻身前十。招商银行此次排名上升，从2024年的第10位升至第8位，而交通银行 的排名保持在第9位不变。 此外，"50强"还包括邮储银行、兴业银行、中信银行、浦发银行、民生银行、光大银行、平安银行、华夏银行以及北京银行等15家中资银行，相比上一年 度增加1家。 谁是本期榜单黑马？ 从今年的榜单来看，招商银行一级资本同比增长11.3%，增速在上述15家中资银行中排名首位 ...

中国科协副主席、中国科学院院士潘建伟，中国人工智能学会理事长、中国工程院院士戴琼海，中国海 洋学会副理事长、中国工程院院士李家彪，中国作物学会理事长、中国农学会副会长、中国工程院院士 万建民，中国可再生能源学会理事长、中国工程院院士谭天伟，分别围绕量子技术、人工智能、深海科 技、种业振兴、生物制造等主题作主旨报告。 主论坛上，中国科协还发布2025重大科学问题、工程技术难题和产业技术问题，包括具有引领性、创新 性、战略性的30个问题难题，推动研判未来科技发展趋势，前瞻谋划前沿科技领域与研究方向。 来源：中国新闻网 中新网北京7月6日电 (记者 孙自法)第二十七届中国科协年会主论坛7月6日在北京举行，中国科协主席 万钢出席并致辞，中国科协党组书记贺军科主持主论坛，五位院士专家应邀作主旨报告。 中国科协主席万钢出席主论坛并致辞。中新网记者 孙自法 摄 万钢表示，本届年会旨在紧跟世界科技前沿发展态势，锚定科技强国目标，交流新理论、新观点、新学 说，探讨新领域、新赛道、新机遇。科协组织将致力于把握科技前沿的发展态势，丰富高质量科技供 给；发挥跨界融合的组织优势，开展高水平科技咨询；倡导务实开放的会风学风，促进高效率学 ...

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan and identify innovative technologies and products that will sustain the industry's vitality [1]. Group 2: Organizing Institutions - The conference is organized by Ningbo Detai Zhongyan Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. Group 3: Highlights of the Conference - The conference will feature forums and closed-door activities to gain insights into the development trends of biomanufacturing during the 14th Five-Year Plan, exploring new products, technologies, and collaborations [4]. - There will be over 100 financing project roadshows to discover new cooperation opportunities [4]. - Key industry leaders, top universities, and capital from industrial parks will gather to discuss advancements in the biomanufacturing sector [4]. Group 4: Agenda and Special Activities - The first day will include a closed-door seminar focusing on the development trends and growth points of biomanufacturing, inviting 30 industry leaders and experts for in-depth discussions [7]. - The second and third days will feature a macro forum on biomanufacturing, covering the development trends and progress of policies related to the industry [10]. Group 5: Specialized Forums - The conference will host specialized forums on various topics, including green chemicals and new materials, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. - Each forum will address specific themes such as the development of bio-based chemicals, green manufacturing technologies, and the application of AI in biomanufacturing processes [11].

Core Viewpoint - O-acetyl-L-homoserine (OAH) is a significant platform compound for producing L-methionine and other valuable chemicals, with recent advancements in sustainable production methods using E. coli, achieving a record yield of 94.1 g/L through innovative metabolic engineering strategies [1][16]. Group 1: Research Content and Key Technical Breakthroughs - The team enhanced OAH production by integrating a dual-module approach with L-homoserine and MetX, increasing initial yield from 5.29 g/L to 8.30 g/L, a 56.9% improvement [3]. - A dynamic regulation strategy for acetyl-CoA was developed, leading to an OAH yield of 11.59 g/L by optimizing multiple pathways and reducing competition [4]. - The use of sRNA for identifying rate-limiting steps in OAH synthesis revealed four critical areas for optimization, including precursor carbon flux distribution and amino supply [7]. - A multi-node fine-tuning approach led to a series of yield improvements, with the final strain OAH33 achieving 19.40 g/L by addressing nutrient deficiencies and optimizing metabolic pathways [12]. Group 2: Production Optimization Techniques - The innovative two-stage pH control in a 5 L bioreactor allowed for the efficient synthesis of OAH, achieving a yield of 94.1 g/L within 68.7 hours, enhancing production by 15.5%-37.3% compared to single pH control [16]. - The research demonstrated that the combination of ATP turnover enhancement and metabolic pathway optimization significantly improved OAH production, with the final strain OAH37 achieving a yield of 20.08 g/L, a 137% increase from the initial strain [14]. Group 3: Future Research and Development - The findings from this research are set to be published in "Metabolic Engineering" in July 2025, indicating ongoing advancements in the field of synthetic biology and metabolic engineering [17].

Core Viewpoint - The "15th Five-Year Plan" marks a critical period for the comprehensive rise of China's biomanufacturing industry, aiming for an added value of over 4 trillion yuan and a penetration rate exceeding 8% [3]. Group 1: Strategic Goals - The key objective during the "15th Five-Year Plan" is to achieve an added value of over 4 trillion yuan in advanced biomanufacturing and related services, with a target penetration rate of over 8% [3]. - The industry is expected to transition towards mid-to-high-end development [3]. Group 2: Development Framework - The plan emphasizes the establishment of three major systems: innovation, industry, and management services [4]. - A "7+1" biomanufacturing industry system will be accelerated, which includes biopharmaceuticals, bio-based chemicals and materials, bioenergy, fermentation, bioengineering food, animal feed, biotechnology equipment, and bio-services [4]. Group 3: Industry Events - The 2025 SynBioCon will be held in Ningbo, Zhejiang, focusing on the intersection of AI and biomanufacturing, along with four application areas: green chemicals and new materials, future food, future agriculture, and beauty raw materials [14]. - The conference aims to explore the development trends of the biomanufacturing industry during the "15th Five-Year Plan" and identify innovative technologies and products that will sustain the industry's vitality [14].

Group 1 - The Chinese Association for Science and Technology has released significant scientific, engineering, and industrial technology issues for 2025 [1] - Ten frontier scientific issues include topics such as the topology and geometric classification of manifolds, the nature and mass origin of the Higgs particle, and the feasibility of using quasi-metals as substitutes for transition metals in precise synthesis and catalytic reactions [2] - Ten engineering technology challenges focus on integrated algorithms for complex model design, simulation, and manufacturing, as well as technologies for deep-sea mining equipment and environmental disturbance suppression [2] - Ten industrial technology issues address breakthroughs in high-end equipment for large-scale seawater desalination, improvements in the oxidation resistance of ultra-supercritical steam turbine blades, and the development of autonomous mining technologies for deep space resource exploration [2][3]

Group 1 - The 17th China Bioindustry Conference will be held from September 4 to September 6, 2025, in Wuhan, focusing on "Biomanufacturing Driving Industrial Transformation, Technology Integration Leading a New Economic Chapter" [1] - The conference is supported by various national ministries and organized by 17 national academic associations, responding to the "14th Five-Year Plan" for bioeconomic development [1][2] - Wuhan has successfully hosted multiple editions of the conference since 2016, establishing itself as a key hub for the life and health industry with over 4,200 well-known companies, including Pfizer and China National Pharmaceutical Group [2] Group 2 - The conference will feature a three-dimensional system comprising "Top-level Summit - Industrial Closed Loop - Global Events," with five core segments including strategic guidance, technological frontiers, industrial ecology, international cooperation, and innovation incubation [3] - Key activities will include high-level forums, specialized sub-forums on gene editing and AI pharmaceuticals, and a 10,000 square meter immersive exhibition area showcasing cutting-edge biomanufacturing achievements [3] - The event aims to create a cross-regional collaboration network covering the entire chain from R&D to finance, and will also promote global technology transfer through international partnerships, such as with a delegation from Cuba [3]

Group 1 - The 20th China International Small and Medium Enterprises Expo was held in Guangzhou from June 27 to 30, attracting over 10,000 buyers and achieving intended transaction amounts exceeding 100 billion yuan [2] - Guangdong is home to 835.71 million enterprises, with small and medium enterprises (SMEs) accounting for over 90% of the total, indicating their significant role in the province's economic development [3] - SMEs in Guangdong are actively involved in both traditional and emerging industries, contributing to the continuous growth of various sectors [3] Group 2 - Innovative products showcased at the expo include a kung fu robot, an intelligent coffee machine capable of creating multiple designs in 90 seconds, and a running "robot dog," highlighting the technological advancements of SMEs [4] - As of the end of 2024, Guangdong aims to cultivate over 50,000 innovative SMEs and more than 27,000 specialized and innovative SMEs, with 2,089 "little giant" enterprises leading the nation [4] - The Guangdong Provincial Department of Industry and Information Technology announced the addition of 55 new provincial-level characteristic industrial clusters, bringing the total to 133, covering various industries such as drones, new energy, and biomedicine [5] Group 3 - In 2023, the total output value of characteristic industrial clusters in Guangdong reached 997.32 billion yuan, a year-on-year increase of 12.87%, with 42 clusters exceeding 10 billion yuan in output [5] - R&D expenditure for these clusters was approximately 50.38 billion yuan, reflecting a 12.99% increase, with a research intensity of 5.05% [5] - SMEs are increasingly recognized as a key support for the resilience of Guangdong's economy, despite their smaller size, they possess significant potential [5]

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan and identify innovative technologies and products that will sustain the industry's vitality [1]. Group 2: Organizers and Highlights - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. - Key highlights include forums on biomanufacturing trends, youth innovation sharing, project roadshows, and participation from leading enterprises, top universities, and investment institutions [4]. Group 3: Agenda and Special Activities - The first day features a closed-door high-level seminar focusing on the development trends and growth points of biomanufacturing, with 30 industry leaders and experts invited [7]. - The second and third days will include a macro forum on biomanufacturing, specialized sub-forums on green chemicals, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. Group 4: Focus Areas in Sub-forums - Sub-forum topics include the development of bio-based chemicals, green manufacturing technologies for fine chemicals, and the use of non-food raw materials for high-value product development [11]. - AI applications in biomanufacturing will also be discussed, including enzyme discovery and industrial fermentation process control [11].

Policy Support - Shenzhen has introduced 32 policy measures to support the entire pharmaceutical and medical device industry chain, focusing on areas such as preclinical research, clinical trials, registration approval, production, and market application [1][2] - The measures emphasize support for emerging technologies and new business models, including "AI+" in pharmaceuticals, biomanufacturing, cell and gene therapy, pet pharmaceuticals, rare disease drugs, and traditional Chinese medicine [1][2] Financial Incentives - The measures provide significant financial rewards for innovative drug development, offering up to 30 million yuan for successful clinical trials of Class 1 innovative drugs [2] - Financial support for pet pharmaceuticals includes rewards of 300,000 yuan, 200,000 yuan, and 100,000 yuan for different categories of new veterinary drugs, with a cap of 500,000 yuan per enterprise annually [2] Clinical Trial Enhancements - Shenzhen aims to establish an international clinical trial center in the Greater Bay Area, optimizing clinical trial processes to reduce internal approval times to within 25 weeks [3] - The measures support the integration of innovative drugs and medical devices, expanding the "Hong Kong-Macau Drug and Device Pass" to include more medical institutions [3] Infrastructure Development - Shenzhen plans to allocate at least 200,000 square meters of industrial land and 1 million square meters of specialized parks annually, focusing on "AI+ pharmaceuticals" and synthetic biology [3] - Key areas like Guangming Science City and Pingshan National Bio-Industry Base will develop an ecosystem combining parks and platforms with public service facilities [3] Talent Acquisition - The measures include a global talent recruitment plan targeting high-level professionals in cell and gene therapy, with a focus on creating a favorable environment for talent development [4] - Innovations in the clinical research talent evaluation system will incorporate research achievements into promotion criteria, alongside housing and education support [4]